Compare ADMA Biologics Inc (ADMA) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? ADMA Biologics Inc trades at $9.86 (market cap $2.22B), while Alnylam Pharmaceuticals, Inc. trades at $221.7 (market cap $29.60B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 13.3× ADMA Biologics Inc's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ADMA | ALNY | |
|---|---|---|
Market Cap | $2.22B | $29.60B |
Sector | Health | Health |
52-Week High | $20.38 | $491.22 |
52-Week Low | $7.60 | $205.48 |
Enterprise Value | $2.29B | $27.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
